2 results match your criteria: "USA. Luke.Rothermel@UHHospitals.org.[Affiliation]"

Wild-type IDH1 inhibition enhances chemotherapy response in melanoma.

J Exp Clin Cancer Res

September 2022

Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.

Background: Alternative treatment strategies in melanoma beyond immunotherapy and mutation-targeted therapy are urgently needed. Wild-type isocitrate dehydrogenase 1 (wtIDH1) has recently been implicated as a metabolic dependency in cancer. The enzyme protects cancer cells under metabolic stress, including nutrient limited conditions in the tumor microenvironment.

View Article and Find Full Text PDF